Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now, we re going to talk about a really interesting set of presentations at San Antonio that I think really do have direct implications for clinical practice on Monday and this is the use of genomic tests and in some of the studies, Ki67 in order to try and inform us about how to treat our patients who have higher risk node-positive disease.
Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now I think what we ll do is focus on novel therapy, some of the novel therapies that were presented at San Antonio. We can t be exhaustive, of course, but we ll talk about some of the agents that either are already being used in the clinic or are emerging agents. One area of great interest is oral taxanes. We ve been trying to get oral taxanes for ages. There is a problem with absorpti
Following is a transcript of their remarks:
Rugo: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
Now at San Antonio this year we saw an update of the really interesting monarchE data, the adjuvant trial looking at abemaciclib versus not additional therapy combined with endocrine therapy in the adjuvant setting for 2 years in patients who have quite high-risk early-stage hormone receptor-positive, HER2-negative breast cancer.
Following is a transcript of their remarks:
Hope Rugo, MD: Hello and welcome to this virtual roundtable where we will be discussing some of the key data that emerged from this year s San Antonio Breast Cancer meeting. I m Hope Rugo, professor of medicine at the University of California San Francisco s Comprehensive Cancer Center, and I m joined today by two expert leaders in the field of breast cancer and great colleagues, Dr. Jennifer Litton from the MD Anderson Cancer Center and Dr. Jo Chien from the University of California San Francisco s Comprehensive Cancer Center. Thanks for joining me today.
So today, in our first discussion, we re going to talk about immunotherapy. This generated great interest at San Antonio and, of course, at all of the major meetings today that discussed breast cancer this year in 2020. I think we saw updates on immunotherapy that are potentially practice-changing at ASCO and ESMO Breast Cancer and ESMO, and now at San Antonio. Jo, do you want to start